Estradiol
Kod:9019|CPT:82670|LOINC:2243-4
| Kabi | Estradiol |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Elektrokimyoluminessent immunoanaliz (ECLIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Do not eat for 2–3 hours before the blood draw; water is allowed.
- For children 1–5 years old, withhold food for 2–3 hours before collection.
- If clinically acceptable, pause steroid and thyroid hormone medications for 48 hours prior to collection.
- Avoid strenuous exercise and minimize emotional stress for 24 hours before collection.
- Do not smoke during the 3 hours before collection.
- Confirm biotin use; discontinue high-dose biotin for at least 72 hours before the test.
Qanday foydalanish
Estradiol (E2) testi, shuningdek qon zardobidagi 17-beta-estradiol sifatida ham ma'lum, tuxumdon funksiyasini baholash va amenoreyani tekshirishda, fiziologik holatlar (masalan, homiladorlik)ni patologik sabablardan farqlash zarur bo'lgan kontekstlarda qo'llab-quvvatlaydi. U pubertat vaqti buzilishlarini (masalan, qizlarda erta pubertat) aniqlashga yordam beradi va erkaklarda ginekomastiya yoki feminizatsiyani baholashda ma'lumot beradi. Reproduktiv yoshdagi ayollarda estradiol tahlili fertilitetni baholashga hissa qo'shadi va nazorat qilinadigan tuxumdon stimulyatsiyasi hamda in vitro urug'lantirish sikllari davomida follikula rivojlanishini monitoring qilish uchun qo'llaniladi.
Cheklovlar
Estradiol ayol reproduktiv organlari va ikkilamchi jinsiy belgilar rivojlanishini boshqaruvchi asosiy estrogen hisoblanadi. Uning konsentratsiyasi hayz sikli davomida o'zgaradi: ovulyatsiya arafasida cho'qqiga chiqadi va erta follikulyar fazada eng past nuqtaga tushadi. Qon aylanishidagi darajalari bolalar, erkaklar va postmenopauza davridagi ayollarda reproduktiv yoshdagi ayollarga qaraganda ancha past bo'ladi. Perimenopauzal o'tish davrida estradiol darajalari keng tebranadi va qiymatlar normal siklik fiziologiyada kuzatiladigan ko'rsatkichlar bilan qisman ustma-ust tushishi mumkin. Ketma-ket tahlillarda natijalar bir xil analiz metodologiyasi bilan olinishi kerak, chunki usullararo farqlar taqqoslash imkoniyatiga ta'sir qilishi mumkin.
| O'lchov birligi | pg/mL |
|---|---|
| Referens oraliq | — |
| Ko'rsatmalar | Assessment of pelvic pain in females, Workup of abnormal uterine bleeding, Irregular menstrual cycles, including oligomenorrhea and amenorrhea, Female infertility evaluation and monitoring during controlled ovarian stimulation, Evaluation of early or delayed puberty in girls, Perimenopausal or menopausal symptoms—such as vasomotor complaints or insomnia—and amenorrhea, Gynecomastia or feminization in males; concern for an estrogen-producing tumor |
Natija og'ishlarining mumkin sabablari
Oshgan daraja
- ampicillin
- biotin supplementation (high dose)
- cascara sagrada
- estrogen therapy
- fulvestrant
- glucocorticoids
- phenothiazines
- tetracyclines
Pasaygan daraja
- high-carbohydrate, low-fat diet (eg, vegetarian diet)
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 1 mL (min 0.7 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Gordon CM. Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med. 2010 Jul 22; 363(4):365-371. PubMed 20660404Kiel DP, Baron JA, Plymate SR, Chute CG. Sex hormones and lipoproteins in men. Am J Med. 1989 Jul; 87(1):35-39. PubMed 2787120Pont A, Goldman ES, Sugar AM, Siiteri PK, Stevens DA. Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med. 1985 Aug; 145(8):1429-1431. PubMed 4040740Segal KR, Dunaif A, Gutin B, Albu J, Nyman A, Pi-Sunyer FX. Body composition, not body weight, is related to cardiovascular disease risk factors and sex hormone levels in men. J Clin Invest. 1987 Oct; 80(4):1050-1055. PubMed 3654969Stewart MO, Whittaker PG, Persson B, Hanson U, Lind T. A longitudinal study of circulating progesterone, oestradiol, hCG and hPL during pregnancy in type 1 diabetic mothers. Br J Obstet Gynaecol. 1989 Apr; 96(4):415-423. PubMed 2751954Studd J, Savvas M, Waston N, Garnett T, Fogelman I, Cooper D. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol. 1990 Nov; 163(5 Pt 1):1474-1479. PubMed 2240090